Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton

Telomerase is a cellular ribonucleoprotein reverse transcriptase that plays a crucial role in telomere maintenance. This enzyme is expressed in approximately 90% of human tumors, but not in the majority of normal somatic cells. Imetelstat sodium (GRN163L), is a 13-mer oligonucleotide N3′→P5′ thio-phosphoramidate lipid conjugate, which represents the latest generation of telomerase inhibitors targeting the template region of the human functional telomerase RNA (hTR) subunit. In preclinical trials, this compound has been found to inhibit telomerase activity in multiple cancer cell lines, as well as in vivo xenograft mouse models. Currently, GRN163L is being investigated in several clinical trials, including a phase II human non-small cell lung cancer clinical trial, in a maintenance setting following standard doublet chemotherapy. In addition to the inhibition of telomerase activity in cancer cell lines, GRN163L causes morphological cell rounding changes, independent of hTR expression or telomere length. This leads to the loss of cell adhesion properties; however, the mechanism underlying this effect is not yet fully understood. In the present study, we observed that GRN163L treatment leads to the loss of adhesion in A549 lung cancer cells, due to decreased E-cadherin expression, leading to the disruption of the cytoskeleton through the alteration of actin, tubulin and intermediate filament organization. Consequently, the less adherent cancer cells initially cease to proliferate and are arrested in the G1 phase of the cell cycle, accompanied by decreased matrix metalloproteinase-2 (MMP-2) expression. These effects of GRN163L are independent of its telomerase catalytic activity and may increase the therapeutic efficacy of GRN163L by decreasing the adhesion, proliferation and metastatic potential of cancer cells in vivo.

[1]  D. Riordan,et al.  Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors. , 2015, Clinical journal of oncology nursing.

[2]  W. An,et al.  Actin disruption agents induce phosphorylation of histone H2AX in human breast adenocarcinoma MCF-7 cells. , 2011, Oncology reports.

[3]  Q. Wang,et al.  The Role of Matrix Metalloproteinase 2 on the Survival of Patients with Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis , 2010, Cancer investigation.

[4]  Sergei M Gryaznov,et al.  Oligonucleotide N3′→P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents , 2010, Chemistry & biodiversity.

[5]  E. Perez.  Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance , 2009, Molecular Cancer Therapeutics.

[6]  Changyu Shen,et al.  The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel , 2009, Molecular Cancer Therapeutics.

[7]  E. Scarpi,et al.  Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. , 2009, Chest.

[8]  T. Svitkina,et al.  Imaging cytoskeleton components by electron microscopy. , 2009, Methods in molecular biology.

[9]  C. Harley,et al.  Telomerase and cancer therapeutics , 2008, Nature Reviews Cancer.

[10]  K. Syrigos,et al.  Targeted therapies for non-small cell lung cancer. , 2007, Current pharmaceutical design.

[11]  E. Hiyama,et al.  Telomere and telomerase in stem cells , 2007, British Journal of Cancer.

[12]  J. Shay,et al.  Antiadhesive effects of GRN163L--an oligonucleotide N3'->P5' thio-phosphoramidate targeting telomerase. , 2007, Cancer research.

[13]  J. Shay,et al.  In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. , 2005, Cancer research.

[14]  C. Harley,et al.  Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition , 2005, Oncogene.

[15]  M. Blasco.  Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.

[16]  Lin Kah Wai.  Telomeres, telomerase, and tumorigenesis--a review. , 2004, MedGenMed : Medscape general medicine.

[17]  R. Khokha,et al.  Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development , 2003, British Journal of Cancer.

[18]  N. Pećina-Šlaus.  Tumor suppressor gene E-cadherin and its role in normal and malignant cells , 2003, Cancer Cell International.

[19]  J. Shay,et al.  Telomerase: a target for cancer therapeutics. , 2002, Cancer cell.

[20]  K. Collins,et al.  Telomerase in the human organism , 2002, Oncogene.

[21]  E. Blackburn.  Switching and Signaling at the Telomere , 2001, Cell.

[22]  J. Soria,et al.  [Telomeres, telomerase and cancer]. , 1997, Bulletin du cancer.

[23]  D. Lloyd,et al.  Oligonucleotide N3'-->P5' phosphoramidates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.